The Elizabeth Morris Lab

Elizabeth Morris: Publications


Original Research

Sutton EJ, Oh JH, Dashevsky BZ, Veeraraghavan H, Apte AP, Thakur SB, Deasy JO, Morris EA. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. J Magn Reson Imaging. 2015 Nov;42(5):1398-406. doi: 10.1002/jmri.24890. PubMed Central PMCID: PMC4784421.

Sutton EJ, Dashevsky BZ, Oh JH, Veeraraghavan H, Apte AP, Thakur SB, Morris EA, Deasy JO. Breast cancer molecular subtype classifier that incorporates MRI features. J Magn Reson Imaging. 2016 Jul;44(1):122-9. doi: 10.1002/jmri.25119. PubMed Central PMCID: PMC5532744.

Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, Giger ML. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.  Radiology. 2016 Nov;281(2):382-391. PubMed Central PMCID: PMC5069147.

Thakur SB, Durando M, Milans S, Cho GY, Gennaro L, Sutton EJ, Giri D, Morris EA. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score. J Magn Reson Imaging. 2018 Feb;47(2):401-409. doi: 10.1002/jmri.25796. PubMed Central PMCID: PMC5741548.

Veeraraghavan H, Dashevsky BZ, Onishi N, Sadinski M, Morris E, Deasy JO, Sutton EJ. Appearance Constrained Semi-Automatic Segmentation from DCE-MRI is Reproducible and Feasible for Breast Cancer Radiomics: A Feasibility Study. Sci Rep. 2018 Mar  19;8(1):4838. doi: 10.1038/s41598-018-22980-9. PubMed Central PMCID: PMC5859113.

Pinker K, Moy L, Sutton EJ, Mann RM, Weber M, Thakur SB, Jochelson MS, Bago-Horvath Z, Morris EA, Baltzer PA, Helbich TH. Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging. Invest Radiol. 2018 Apr 3. doi: 10.1097/RLI.0000000000000465.

van der Velden BHM, Sutton EJ, Carbonaro LA, Pijnappel RM, Morris EA, Gilhuijs KGA. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer  patients. Eur Radiol. 2018 May 7. doi: 10.1007/s00330-018-5470-7. 

Horvat JV, Durando M, Milans S, Patil S, Massler J, Gibbons G, Giri D, Pinker  K, Morris EA, Thakur SB. Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis. Eur Radiol. 2018 Jun;28(6):2516-2524. doi: 10.1007/s00330-017-5202-4. PubMed Central PMCID: PMC6089248.


Pinker K, Chin J, Melsaether AN, Morris EA, Moy L. Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology. 2018 Jun;287(3):732-747. doi: 10.1148/radiol.2018172171. Review.